Abstract
Joint inflammation in rheumatoid arthritis (RA) induces local periarticular osteoporosis. Generalised bone mineral density (BMD) decrease concerns approximately 50% of rheumatic patients. Both types of bone mass depletion can issue from cytokine-induced (TNF-α, IL-1, IL-6) osteoclasts’ activation, osteoprotegerin and its ligand’s (RANKL) function disorders, patients’ immobilisation and glucocorticosteroid (GCS) intake, as well as from hormonal alterations in postmenopausal women, predominate among RA individuals. The aim of the study was to compare serum concentrations of marker of bone formation—serum aminoterminal propeptide of type I collagen (PINP), and bone resorption, carboxy (C) terminal telopeptide (Ctx), bone turnover markers in RA and osteoarthritis (OA) patients and in RA groups of different disease activity, different degree of joint damage and the history of GCS intake. A total of 50 RA female patients and 50 women with knee OA were included in the study. Blood for morphology and biochemistry laboratory tests was taken. Joint X-rays to establish OA and RA diagnosis and the degree of RA progression, as well as DEXA BMD measurements were performed. PINP and Ctx concentrations were assessed. In RA patients the number of swollen and painful joints, the duration of morning stiffness, visual analogue scale values and Waaler–Rose’s test activity were recorded. The Disease Activity Index (DAS 28) was counted from the appropriate formula. No differences in bone turnover markers’ concentrations were noted neither between RA and OA patients nor between the RA group when compared to the one without the history of GCS use. Bone turnover markers’ concentrations in RA were proportional to the number of swollen and painful joints. However, no correlation was found between the markers’ concentrations and RA activity assessed by DAS 28 or by laboratory means. Ctx concentrations were higher in patients at II degree joint damage according to Larsen and Dale’s than at more advanced stages. Ctx concentrations decreased with the disease duration. Serum morphogenesis and resorption markers’ concentrations change in course of RA indicating the decrease in bone metabolic activity with the disease duration and progression. High RA activity and severity correlate with increased markers’ levels—the resorption one. The influence of GCS on bone metabolism in RA requires further study.
Similar content being viewed by others
References
Suzuki Y, Tanihara M, Ichikawa Y et al (1995) Periarticular osteopenia in adjuvant-induced arthritis: role of interleukin-1 in decreased osteogenic and increased resorptive potential of bone marrow cells. Ann Rheum Dis 54:484–490. doi:10.1136/ard.54.6.484
Dequeker J, Maenaut J, Verwilghen J et al (1995) Osteoporosis in rheumatoid arthritis. Clin Exp Rheumatol 13(Suppl 12):S21–S26
Calvo MS, Eyre DR, Gunberg CM (1996) Molecular basis and clinical application of biological markers of bone turnover. Endocrinol Rev 17:333–368. doi:10.1210/er.17.4.333
Arnett FC, Edworthy SM, Block DA et al (1988) The American Rheumatism Association, 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31:315–324. doi:10.1002/art.1780310302
Altman R (1991) Classification of disease: osteoarthritis. Semin Arthritis Rheum 20(Suppl 2):40–47. doi:10.1016/0049-0172(91)90026-V
Van der Heijde DMFM, van’t Hof MA, van Riel PLCM et al (1993) Development of a disease activity score based on judgement in clinical practice by rheumatologists. J Rheumatol 20:579–581
Larsen A, Dale K, Eek M (1977) Radiographic evaluation of rheumatoid arthritis and related conditions by standard reference films. Acta Radiol Diagn (Stockh) 18:481–491
Robert R, Sokal F, Rohlf J (1986) Biometry. Freeman, New York, pp 354–359, 691–714
Garnero P, Solrnay-Rendu E, Clausrat B et al (2000) Biochemical markers of bone turnover, endogenous hormones and the risk of fractures in postmenopausal women. The OFFELY study. J Bone Miner Res 15:1526–1536. doi:10.1359/jbmr.2000.15.8.1526
Garnero P, Delmas PD (2004) Noninvasive techniques for assessing skeletal changes in inflammatory arthritis: bone biomarkers. Curr Opin Rheumatol 16:428–434. doi:10.1097/01.moo.0000127830.72761.00
Demers LM, Kleerekoper M (1994) Recent advances in biochemical markers of bone turnover. Clin Chem 40:1994–1995
Dias A, Lopes Vaz A, Hargreaves M et al (1989) Biomarkers in secondary osteoporosis. Clin Rheum Suppl 2:89–94. doi:10.1007/BF02207241
Chapurlat RD, Garnelo P, Breart G et al (2000) Serum type I collagen break down product (serum Ctx) predicts hip fracture risk in elderly women: The EPIDOS Study. Bone 27:283–286. doi:10.1016/S8756-3282(00)00325-2
Catrina AI, af Klint E, Ernestam S et al (2006) Anti-tumor necrosis factor therapy increases synovial osteoprotegerin expression in rheumatoid arthritis. Arthritis Rheum 54:76–81. doi:10.1002/art.21528
Compston IE, Crawley EC, Evans C et al (1988) Spinal trabecular bone mineral content in patients with non-steroid treated rheumatoid arthritis. Ann Rheum Dis 47:660–664. doi:10.1136/ard.47.8.660
Cortet B, Filipo RM, Pigny P et al (1998) Is bone turnover a determinant of bone mass in rheumatoid arthritis? J Rheumatol 25:2339–2344
Garnero P, Jouvenne P, Buchs N et al (1999) Uncoupling of bone metabolism in rheumatoid arthritis patients with or without joint destruction: assessment with serum type I collagen break down products. Bone 24:381–385. doi:10.1016/S8756-3282(98)00193-8
Gough AKS, Liley J, Eyre S et al (1994) Generalised bone loss in patients with early rheumatoid arthritis. Lancet 344:23–27. doi:10.1016/S0140-6736(94)91049-9
Gough A, Sambroock P, Delvin J et al (1998) Osteoclastic activation in the principal mechanism leading to secondary osteoporosis in rheumatoid arthritis. J Rheumatol 25:1282–1298
Momohara S, Okamoto H, Yago T et al (2005) The study of bone mineral density and bone turnover markers in postmenopausal women with active rheumatoid arthritis. Mod Rheumatol 15:410–414. doi:10.1007/s10165-005-0435-5
Nakayama H (2007) Osteoporosis in the patients with rheumatoid arthritis (3): the efficacy and the selection of the osteoporosis therapeutic drug. Clin Calcium 17:1607–1612
Sinigaglia L, Varenna M, Girasole G et al (2006) Epidemiology of osteoporosis in rheumatic diseases. Rheum Dis Clin North Am 32:631–658. doi:10.1016/j.rdc.2006.07.002
de Nijs RN, Jacobs JW, Bijsma JW et al (2001) Prevalence of vertebral deformities and symptomatic vertebral fractures in corticosteroid treated patients with rheumatoid arthritis. Rheumatology (Oxf) 40:1375–1383. doi:10.1093/rheumatology/40.12.1375
Huusko TM, Korpela M, Karppi P et al (2001) Threefold increased risk of hip fractures with rheumatoid arthritis in central Finland. Ann Rheum Dis 60:521–522. doi:10.1136/ard.60.5.521
Garton MJ, Reid DM (1993) Bone mineral density of the hip and the spine in men with rheumatoid arthritis, effects of low dose corticosteroids. Arthritis Rheum 36:222–225
Korczowska I, Olewicz-Gawlik A, Trefler J et al (2007) Does low-dose and short-term glucocorticoids treatment increase the risk of osteoporosis in rheumatoid arthritis female patients? Clin Rheumatol 27(5):565–572
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Wisłowska, M., Jakubicz, D., Stępień, K. et al. Serum concentrations of formation (PINP) and resorption (Ctx) bone turnover markers in rheumatoid arthritis. Rheumatol Int 29, 1403–1409 (2009). https://doi.org/10.1007/s00296-009-0867-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00296-009-0867-x